In this study, we screened 136 patients with stage III/IV NSCLC, after PSM (cut‐off = 0.01) the selected 88 patients were administered 2 different doses of rh‐endostatin combined with platinum‐based chemotherapy or platinum‐based chemotherapy only, and their efficacy and safety were compared. This evidence concerns the gene COL18A1 and non-small cell lung carcinoma.